These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Gestational trophoblastic neoplasia after human chorionic gonadotropin normalization in a retrospective cohort of 7761 patients in France. Descargues P; Hajri T; Massardier J; Lotz JP; Devouassoux-Shisheboran M; Allias Montmayeur F; You B; Golfier F; Bolze PA Am J Obstet Gynecol; 2021 Oct; 225(4):401.e1-401.e9. PubMed ID: 34019886 [TBL] [Abstract][Full Text] [Related]
4. Treatment of nonmetastatic and metastatic low-risk gestational trophoblastic neoplasia: factors associated with resistance to single-agent methotrexate chemotherapy. Chapman-Davis E; Hoekstra AV; Rademaker AW; Schink JC; Lurain JR Gynecol Oncol; 2012 Jun; 125(3):572-5. PubMed ID: 22449733 [TBL] [Abstract][Full Text] [Related]
5. Human Chorionic Gonadotropin (hCG) Regression Curve for Predicting Response to EMA/CO (Etoposide, Methotrexate, Actinomycin D, Cyclophosphamide and Vincristine) Regimen in Gestational Trophoblastic Neoplasia. Rattanaburi A; Boonyapipat S; Supasinth Y Asian Pac J Cancer Prev; 2015; 16(12):5037-41. PubMed ID: 26163637 [TBL] [Abstract][Full Text] [Related]
6. Human chorionic gonadotropin (hCG) regression normograms for patients with high-risk gestational trophoblastic neoplasia treated with EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide and vincristine) chemotherapy. Lybol C; Westerdijk K; Sweep FCGJ; Ottevanger PB; Massuger LFAG; Thomas CMG Ann Oncol; 2012 Nov; 23(11):2903-2906. PubMed ID: 22730100 [TBL] [Abstract][Full Text] [Related]
7. [Therapeutic evaluation of cisplatin, etoposide, and bleomycin chemotherapy regimen in high-risk gestational trophoblastic neoplasia]. Song SQ; Zhang GN Zhonghua Fu Chan Ke Za Zhi; 2012 Aug; 47(8):571-6. PubMed ID: 23141175 [TBL] [Abstract][Full Text] [Related]
8. Relapsed or refractory gestational trophoblastic neoplasia treated with the etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EP-EMA) regimen. Mao Y; Wan X; Lv W; Xie X Int J Gynaecol Obstet; 2007 Jul; 98(1):44-7. PubMed ID: 17481633 [TBL] [Abstract][Full Text] [Related]
9. Management and survival of patients with FIGO high-risk gestational trophoblastic neoplasia: the U.K. experience, 1995-2010. Agarwal R; Alifrangis C; Everard J; Savage PM; Short D; Tidy J; Fisher RA; Sebire NJ; Harvey R; Hancock BW; Coleman RE; Seckl MJ J Reprod Med; 2014; 59(1-2):7-12. PubMed ID: 24597279 [TBL] [Abstract][Full Text] [Related]
10. Predictors for single-agent resistance in FIGO score 5 or 6 gestational trophoblastic neoplasia: a multicentre, retrospective, cohort study. Braga A; Paiva G; Ghorani E; Freitas F; Velarde LGC; Kaur B; Unsworth N; Lozano-Kuehne J; Dos Santos Esteves APV; Rezende Filho J; Amim J; Aguiar X; Sarwar N; Elias KM; Horowitz NS; Berkowitz RS; Seckl MJ Lancet Oncol; 2021 Aug; 22(8):1188-1198. PubMed ID: 34181884 [TBL] [Abstract][Full Text] [Related]
11. Comparing cisplatin-based combination chemotherapy with EMA/CO chemotherapy for the treatment of high risk gestational trophoblastic neoplasia. Lybol C; Thomas CM; Blanken EA; Sweep FC; Verheijen RH; Westermann AM; Boere IA; Reyners AK; Massuger LF; van Hoesel RQ; Ottevanger PB Eur J Cancer; 2013 Mar; 49(4):860-7. PubMed ID: 23099004 [TBL] [Abstract][Full Text] [Related]
13. Low-risk gestational trophoblastic neoplasia and methotrexate resistance: predictors of response to treatment with actinomycin D and need for combination chemotherapy. Growdon WB; Wolfberg AJ; Goldstein DP; Feltmate CM; Chinchilla ME; Lieberman ES; Berkowitz RS J Reprod Med; 2010; 55(7-8):279-84. PubMed ID: 20795339 [TBL] [Abstract][Full Text] [Related]
14. EMACO for treatment of gestational trophoblastic neoplasia: A multinational multicenter study. Jareemit N; Therasakvichya S; Freitas F; Paiva G; Ramírez LAC; Berkowitz RS; Horowitz NS; Maestá I; Fülöp V; Braga A; Elias KM Gynecol Oncol; 2023 Mar; 170():114-122. PubMed ID: 36682089 [TBL] [Abstract][Full Text] [Related]
15. Is there uniformity in definitions and treatment of gestational trophoblastic disease in Europe? Frijstein MM; Lok CAR; Coulter J; van Trommel NE; Ten Kate-Booij MJ; Golfier F; Seckl MJ; Massuger LFAG Int J Gynecol Cancer; 2019 Jan; 29(1):108-112. PubMed ID: 30640691 [TBL] [Abstract][Full Text] [Related]
16. Comparison of methotrexate, actinomycin D, and etoposide for treating low-risk gestational trophoblastic neoplasia. Baptista AM; Belfort P Int J Gynaecol Obstet; 2012 Oct; 119(1):35-8. PubMed ID: 22877838 [TBL] [Abstract][Full Text] [Related]
17. The WHO score predicts treatment outcome in low risk gestational trophoblastic neoplasia patients treated with weekly intramuscular methotrexate. Gilani MM; Fariba B; Behtash N; Ghaemmaghami F; Moosavi AS; Rezayof E J Cancer Res Ther; 2013; 9(1):38-43. PubMed ID: 23575072 [TBL] [Abstract][Full Text] [Related]
18. Serum hCG level and rising world health organization score at second-line chemotherapy (pulse dactinomycin): poor prognostic factors for methotrexate-failed low-risk gestational trophoblastic neoplasia. Kang WD; Kim CH; Cho MK; Kim JW; Cho HY; Kim YH; Choi HS; Kim SM Int J Gynecol Cancer; 2010 Nov; 20(8):1424-8. PubMed ID: 21051988 [TBL] [Abstract][Full Text] [Related]
19. Importance of salvage therapy in the management of high-risk gestational trophoblastic neoplasia. Lurain JR; Schink JC J Reprod Med; 2012; 57(5-6):219-24. PubMed ID: 22696816 [TBL] [Abstract][Full Text] [Related]
20. The added value of hysterectomy in the management of gestational trophoblastic neoplasia. Eysbouts YK; Massuger LFAG; IntHout J; Lok CAR; Sweep FCGJ; Ottevanger PB Gynecol Oncol; 2017 Jun; 145(3):536-542. PubMed ID: 28390821 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]